Imetelstat · Rytelo
RNA / oligonucleotide
Also known as GRN163L
Evidence outlook
Approved: Myelodysplastic Syndromes
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (1)
- Transfusion-dependent anaemia in adults with very low, low or intermediate-1 risk myelodysplastic syndromes without isolated del(5q) who had an unsatisfactory response to or are ineligible for erythropoiesis-stimulating agents; marketing authorisation holder Geron Netherlands B.V.
Development in Myelofibrosis stopped (2026-10) after a negative readout. Development continues in another indication. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02598661 NCT02598661 · Myelodysplastic Syndromes The Phase 3 part randomly assigned 178 participants to imetelstat or a matching placebo, with participants and investigators blinded. The primary endpoint, going at least 8 weeks without a red blood cell transfusion, was met: 39.8% versus 15.0% (p<0.001). The protocol's sample-size calculation called for about 170 randomized participants, and 178 were randomized. Registry: NCT02598661 | 2/3 | Phase 2: Percentage of Participants Without Any Red Blood Cell (RBC) Transfusion During Any Consecutive 8-Weeks Period (All Participants) (Up to 5 years in Phase 2); Phase 2: Percentage of Participants Without Any RBC Transfusion During Any Consecutive 8-Weeks Period in Target Population (Up to 5 years in Phase 2); Phase 3: Percentage of Participants Without Any RBC Transfusion During Any Consecutive 8-Weeks Period (Up to 3.7 years in Phase 3) 2023-10-13 | Primary results reported. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Competitive landscape
This drug's own stage for Myelodysplastic Syndromes: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Imetelstat (Rytelo): this drug | Approved | RNA / oligonucleotide | Telomerase | Reliable signal | No reviewed efficacy summary in this indication | |
| Azacitidine | Approved | Small molecule | DNMT1 (DNA methyltransferase 1) | not yet graded | No reviewed efficacy summary in this indication | |
| Decitabine / Cedazuridine (Inqovi) | Approved | Small molecule | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition) | Partial signal | Featured results are non-efficacy only in this race | |
| Lenalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | not yet graded | No reviewed efficacy summary in this indication | |
| Elritercept | Phase 3 | Undisclosed | Activin A/B | not yet graded | No reviewed efficacy summary in this indication | |
| Roxadustat (Evrenzo) | Phase 3 | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | not yet graded | No reviewed efficacy summary in this indication | |
| AND017 | Phase 2 | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | not yet graded | No reviewed efficacy summary in this indication | |
| Momelotinib | Phase 2 | Small molecule | JAK1 / JAK2 / ACVR1 | not yet graded | No reviewed efficacy summary in this indication | |
| R289 | Phase 1/2 | Small molecule | IRAK1/IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08046040 | —(overall) | Undisclosed | CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70 | not yet graded | No reviewed efficacy summary in this indication | |
| REGN17235 | —(overall) | Multispecific antibody | SLC3A2 x CD3 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Rytelo (Imetelstat) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.